

CERTIFICATE OF ANALYSIS

Product: **CANIVERM comprimate á 0,7 g**

Batch No.: **A039-07**

0.7 g

Expiry: **3.9.2022**

Date of production: **4.9.2020**

Results of analysis:

Tests	Release limits	Shelf-life limits	Results
Appearance	Light yellow tablets.		complies
Content of original package	2 x 1 tbl., 6 x 1 tbl., 100 x 1 tbl.		complies
Microbiological quality	It shall comply with Ph. Eur., Article 5.1.4.		complies
Content of fenbendazole	142.5 – 157.5 mg/0.7 g		151.42 mg/0.7 g
Fenbendazole identity	Must comply.		complies
Content of pyrantel embonate	136.8 – 151.2 mg/0.7 g		147.85 mg/0.7 g
Pyrantel identity	Must comply.		complies
Content of praziquantel	47.5 – 52.5 mg/0.7 g		50.66 mg/0.7 g
Praziquantel identity	Must comply.		complies
Weight uniformity of tablets	0.665 – 0.735 g		0.710 g
Impurities of fenbendazole			
- content of oxfendazole	max. 1.0 %		0.00 %
- any individual unidentified impurity	max. 1.0 %		0.00 %
- sum of impurities	max. 3.0 %		0.00 %
Impurities of pyrantel embonate			
- any individual unidentified impurity	max. 1.0 %		0.67 %
- sum of impurities	max. 3.0 %		0.67 %
Impurities of praziquantel			
- any individual unidentified impurity	max. 1.0 %		0.00 %
- sum of impurities	max. 3.0 %		0.00 %
Break down tablets	Must conform.		complies

I certify that this product has been tested in the laboratories of Bioveta a.s. and has been found to meet specification requirements. Preparation is suitable with control regulations of the valid PN No. 316.




25/02/2020
 Mgr. Hana Nezvalová
 HEAD of QC, QP